Some psychedelic assisted therapies, such as MDMA for posttraumatic stress disorder and psilocybin for major depression, are either approaching the end of clinical trials or in the midst of clinical trials that may soon lead to FDA approval. But a prescribed combination of drug plus therapy is a new territory for both clinicians, regulators, and patients. Because of this, the question of how these combined therapies will actually be administered remains an open one of some urgency. In this talk, Andrew Penn, MS, PMHN (Clinical Professor of Nursing, UC San Francisco) and Charles Raison, MD (Director of the Vail Health Behavioral Health Innovation Center) will explore the implications, opportunities, and challenges of this change in how we treatment mental illness from the perspective of multiple stakeholders.
- Provider:University of Wisconsin-Madison Interprofessional Continuing Education Partnership
- Activity Link: https://ce.icep.wisc.edu/node/49616
- Start Date: 2024-07-01 05:00:00
- End Date: 2024-07-01 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours
Psychology: 1.0 hours
Social Work: 1.0 hours - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Jointly Provided
- Registration: Open to all